Jump to content
  • Sign Up
Celiac.com Sponsor:

Celiac.com Sponsor:

  • Join Our Community!

    Get help in our celiac / gluten-free forum.

  • Jefferson Adams

    Safe Way to Inhibit MLCK1 Enzyme Action Could Mean Better Treatment for Irritable Bowel Disease

    Jefferson Adams

    Reviewed and edited by a celiac disease expert.

      The potentially exciting part is that, under experimental inflammatory bowel disease conditions, divertin corrects barrier dysfunction, and prevents disease development and progression. 

    Caption: Image: CC--Oak Ridge National Laboratory

    Celiac.com 04/09/2019 - Epithelial barrier loss is a key factor in many intestinal and systemic diseases. Myosin light chain kinase (MLCK) is a key effector of barrier dysfunction, and a target for a potential treatment, but enzymatic inhibition has unacceptable toxicity. 

    A team of researchers recently demonstrated that a unique domain within the MLCK splice variant MLCK1 directs perijunctional actomyosin ring (PAMR) recruitment.

    Celiac.com Sponsor:

    The research team included W. Vallen Graham, Weiqi He, Amanda M. Marchiando, Juanmin Zha, Gurminder Singh, Hua-Shan Li, Amlan Biswas, Ma. Lora Drizella M. Ong, Zhi-Hui Jiang, Wangsun Choi, Harmon Zuccola, Yitang Wang, James Griffith, Jingshing Wu, Harry J. Rosenberg, Yingmin Wang, Scott B. Snapper, David Ostrov, Stephen C. Meredith, Lawrence W. Miller and Jerrold R. Turner.

    Using the domain structure and multiple screens, they revealed a domain-binding small molecule (divertin) that blocks MLCK1 recruitment without inhibiting enzymatic function. 

    Divertin blocks acute, tumor necrosis factor (TNF)-induced MLCK1 recruitment, in addition to downstream myosin light chain (MLC) phosphorylation, barrier loss, and diarrhea, both in vitro and in vivo. 

    The potentially exciting part is that, under experimental inflammatory bowel disease conditions, divertin corrects barrier dysfunction, and prevents disease development and progression. 

    Beyond applications of divertin in gastrointestinal disease, this general approach to enzymatic inhibition by preventing access to specific sub-cellular sites offers a new model for safe and precise targeting of specific properties of enzymes with numerous functions.

    The development of a safe way to inhibit MLCK1 enzyme action, and which could potentially correct gut barrier dysfunction, and prevent the development and progression of inflammatory bowel disease is exciting news.

    Read more in Nature Medicine


    The researchers are variously affiliated with the Department of Pathology, University of Chicago, Chicago, IL, USA; the Laboratory of Chemical Biology & Signal Transduction, The Rockefeller University, New York, NY, USA; Jiangsu Key Laboratory of Neuropsychiatric Diseases and Cambridge-Suda Genomic Resource Center, Soochow University, and Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China; the Laboratory of Mucosal Barrier Pathobiology, Department of Pathology and the Division of Gastroenterology, Hepatology and Nutrition at Boston Children’s Hospital and Harvard Medical School in Boston, MA, USA; the Department of Pathology, Immunology and Laboratory Medicine, University of Florida, College of Medicine, Gainesville, FL, USA, the Department of Chemistry, University of Illinois at Chicago, Chicago, IL, USA, and Vertex Pharmaceuticals, Boston, MA, USA.

    User Feedback

    Recommended Comments

    There are no comments to display.

    Join the conversation

    You are posting as a guest. If you have an account, sign in now to post with your account.
    Note: Your post will require moderator approval before it will be visible.

    Add a comment...

    ×   Pasted as rich text.   Paste as plain text instead

      Only 75 emoji are allowed.

    ×   Your link has been automatically embedded.   Display as a link instead

    ×   Your previous content has been restored.   Clear editor

    ×   You cannot paste images directly. Upload or insert images from URL.

  • About Me

    Jefferson Adams is Celiac.com's senior writer and Digital Content Director. He earned his B.A. and M.F.A. at Arizona State University, and has authored more than 2,500 articles on celiac disease. His coursework includes studies in science, scientific methodology, biology, anatomy, medicine, logic, and advanced research. He previously served as SF Health News Examiner for Examiner.com, and devised health and medical content for Sharecare.com. Jefferson has spoken about celiac disease to the media, including an appearance on the KQED radio show Forum, and is the editor of the book "Cereal Killers" by Scott Adams and Ron Hoggan, Ed.D.

  • Related Articles

    Jefferson Adams
    Celiac.com 02/24/2015 - I've posted recipes for chicken and beef broth lately, and now it's time for what may be the healthiest of all broths, fish broth.
    Naturally gluten-free fish broth offers a delicious way to promote gut health, and recovery from illness.
    Ideally, fish broth is made from the bones of sole or turbot. Unfortunately, it's hard to get whole sole...

    Jefferson Adams
    Will a new treatment enable people with celiac disease to ditch a gluten-free diet?
    About one in a hundred people in the United States is affected by celiac disease. If you're one of them, you know how hard it can be to maintain a strict gluten-free diet.
    Everyone's got their horror stories about trying to simply eat a meal, only to have a tiny amount of gluten wreck havoc...

    Jefferson Adams
    Celiac.com 12/25/2017 - In the very near future, your personal microbiome may be the key to creating a customized treatment for celiac disease.
    That's because new advances in genome studies are promising to help create a customized, individual approach for treating numerous disorders, including celiac disease. Such individualized treatments may also help to reduce adverse events...

    Jefferson Adams
    Celiac.com 03/20/2019 - Sensitivities to gluten are becoming more common. Patients with celiac disease have wheat-specific immune responses, but researchers have remained uncertain about the potential role of non-wheat proteins in triggering symptoms in celiac or gluten-sensitive patients.
    A team of researchers recently set out to assess the role of non-gluten proteins that...

  • Celiac.com Sponsor:

  • Forum Discussions

    Hi!   Sorry no one had your exact symptoms.  Do you have celiac disease?  Celiac disease is an autoimmune disease that attacks the small intestine.  Once destroyed digesting foods can be difficult because enzymes can not be released, et...
    Sorry, but I am not familiar with those tests.  They are not standard for celiac disease testing which does require you to be on a full gluten diet months before a blood draw or weeks before an endoscopy.   Your symptoms could be celiac di...
    Did you have any positives on the celiac blood tests?  Small intestinal damage can be spotty since it is larger than the size of a tennis court!   If you went on an elimination diet, you probably avoided foods that you had intolerances t...
  • Create New...